From the Editor

NuraLogix, global pioneers of contactless health monitoring, unveiled its Anura™ Telehealth platform at CES 2023. The platform performs continuous health and vital sign measurements while on a video telemedicine call. It uses conventional video cameras to extract facial blood flow information to accurately calculate a host of vital signs and health risk assessments, using only mobile and desktop devices.

Anura is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments using mobile and desktop devices. Unlike smartwatches, health trackers, and rings that track blood flow through light sensors, Anura can do so with a video selfie.

The entire Anura platform is powered by NuraLogix’s patented Transdermal Optical Imaging (TOI™) technology, a novel form of remote photoplethysmography (rPPG). It automatically detects a person’s face, identifies key regions of interest, and extracts blood flow information that is combined with powerful AI data models developed from tens of thousands of patients with multiple health conditions.

Results are delivered within its intuitive app, showing information on dozens of health parameters such as heart rate, breathing rate, and cuffless blood pressure. It provides health risk assessments for some of the most prevalent chronic conditions, including type 2 diabetes, hypertension, cardiovascular disease, and mental health.

Anura Telehealth is designed to enable true, two-way video telemedicine sessions and enhance remote patient monitoring, making these sessions more useful to both patients and healthcare professionals.

“Post-pandemic telemedicine has increasingly become the norm. While convenient and cost-effective, remote visits have until now lacked the ability for health professionals to carry out the routine health checks they would normally perform in the clinical setting,” says Dr. Keith Thompson, chief medical officer at NuraLogix.

The ability to carry out real-time health risk health assessment is a “game changer.” Anura is unique in that it can assess HbA1c, monitor fasting glucose, and assess the risk of type 2 diabetes, hypertension, and hypertriglyceridemia. Its research models have currently appeared in 10 global peer-reviewed research publications, with three additional publications in progress covering topics of hypertension, multi-year cardiovascular risk, diabetes, and fatty liver disease.

Sherrie Trigg

Editor and Director of Medical Content

A video of the technology is available here .